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Abstract
Background: We have identified a set of genes whose relative mRNA expression levels in various solid tumors can be 
used to robustly distinguish cancer from matching normal tissue. Our current feature set consists of 113 gene probes 
for 104 unique genes, originally identified as differentially expressed in solid primary tumors in microarray data on 
Affymetrix HG-U133A platform in five tissue types: breast, colon, lung, prostate and ovary. For each dataset, we first 
identified a set of genes significantly differentially expressed in tumor vs. normal tissue at p-value = 0.05 using an 
experimentally derived error model. Our common cancer gene panel is the intersection of these sets of significantly 
dysregulated genes and can distinguish tumors from normal tissue on all these five tissue types.
Methods: Frozen tumor specimens were obtained from two commercial vendors Clinomics (Pittsfield, MA) and 
Asterand (Detroit, MI). Biotinylated targets were prepared using published methods (Affymetrix, CA) and hybridized to 
Affymetrix U133A GeneChips (Affymetrix, CA). Expression values for each gene were calculated using Affymetrix 
GeneChip analysis software MAS 5.0. We then used a software package called Genes@Work for differential expression 
discovery, and SVM light linear kernel for building classification models.
Results: We validate the predictability of this gene list on several publicly available data sets generated on the same 
platform. Of note, when analysing the lung cancer data set of Spira et al, using an SVM linear kernel classifier, our gene 
panel had 94.7% leave-one-out accuracy compared to 87.8% using the gene panel in the original paper. In addition, 
we performed high-throughput validation on the Dana Farber Cancer Institute GCOD database and several GEO 
datasets.
Conclusions: Our result showed the potential for this panel as a robust classification tool for multiple tumor types on 
the Affymetrix platform, as well as other whole genome arrays. Apart from possible use in diagnosis of early 
tumorigenesis, some other potential uses of our methodology and gene panel would be in assisting pathologists in 
diagnosis of pre-cancerous lesions, determining tumor boundaries, assessing levels of contamination in cell 
populations in vitro and identifying transformations in cell cultures after multiple passages. Moreover, based on the 
robustness of this gene panel in identifying normal vs. tumor, mislabelled or misinterpreted samples can be pinpointed 
with high confidence.
Background
Rapid and accurate classification of cancerous tissue sam-
ples is an unmet scientific and clinical need. Standard
clinical practice in identifying cancer relies on pathologi-
cal examination of biopsy specimens, radiological images
and histology. However, these diagnoses can be incorrect
because of atypical morphologies, or poorly extracted
biopsies. In cases where the pathologist makes an error in
determining whether a surgically resected tumor has suf-
ficient normal cells in its margins, an error could have
significant consequences to the patient. A corroboratory
analysis may also benefit laboratory experiments on cell
lines or tissue samples which might be labelled as cancer-
ous, but might in fact be significantly or wholly contami-
nated by surrounding or externally derived non-
cancerous tissue.
Several previous studies have attempted to find a com-
mon gene signature in multiple neoplasms. One such
group at the NIH has also established a gene panel capa-
ble of distinguishing benign from malignant tumor in
four different tissue types [1]. In terms of diagnosing can-
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cer from normal specifically, two groups from Johns Hop-
kins [2,3] have used different methods to analyse the data
being collected by ONCOMINE http://www.oncom-
ine.com and have attempted to establish a multi-tissue
cancer signature and have claimed and demonstrated
success in classifying cancer from normal tissue. The
main difference between these two approaches is the
algorithm used for feature extraction. Xu et al [4] used a
method called top-scoring pair of groups (TSPG) to
select informative genes which relies on a random sub
sampling of genes. Rhodes et al [2] used a more classical
approach to determine the most significantly differen-
tially expressed genes that treats each gene as an indepen-
dent feature in the dataset. We also use the t-statistic to
determine differential expression, which is similar to
Rhodes et al [2], but do not assume an underlying normal
distribution. Instead, we used an experimentally derived
error model for Affymetrix chips incorporated in the
Genes@Work software suite from IBM Research which is
freely available at: http://www.research.ibm.com/Fun-
Gen/FGDownloads.htm. The experimental model used
in Genes@Work determines p-values based on a multi-
tissue model derived from replicate measurements on
Affymetrix chips to assess stochastic and systematic
(handling) errors in microarray data analysis.
Our training set consists of a proprietary sample set for
normal and cancerous tissue from breast, colon, lung,
prostate and ovary. A detailed description of this data is
available in the methods section. Using this high quality
multi-tissue data set, we applied an integrated informat-
ics strategy which combined targeted bioinformatics and
analytical approaches to identify and validate a panel of
genes to distinguish normal from cancer tissue. We also
demonstrated that an accurate diagnosis of cancer tissue
is possible using modern gene expression arrays.
Methods
Training set sample and microarray data generation
Frozen tumor specimens were obtained from two com-
mercial vendors Clinomics (Pittsfield, MA) and Asterand
(Detroit, MI). The data was obtained from five tissue
types (Prostate: 7 Benign, 2 Normal, 10 Cancer), (Lung:
37 Normal, 29 Cancer), (Ovarian: 24 Normal, 22 Cancer),
(Colon: 4 Benign, 4 Normal, 33 Cancer), (Breast: 6
Benign, 10 Normal, 31 Cancer) [Table 1]. Total RNA was
extracted from 20 to 40 30 μm cryostat sections of tumor
tissues (median 90 mg; range, 40-120 mg) with RNAzol B
(Campro Scientific, Veenendaal, Netherlands). The
median RNA yield was 82 μg (range, 19-240 μg). RNA
quality was checked by use of the Agilent BioAnalyzer,
and samples were profiled only if they had clear distinct
18S and 28S peaks with no minor peaks present, the area
under the 18S and 28S peaks was more than 15% of the
total RNA area, and if the 28S/18S ratio was between 1.2
and 2.0. Biotinylated targets were prepared using pub-
lished methods (Affymetrix, CA) [4] and hybridized to
Affymetrix U133A GeneChips (Affymetrix, CA). Expres-
sion values for each gene were calculated using Affyme-
trix GeneChip analysis software MAS 5.0. Chips were
rejected if average intensity was < 40 or if the background
signal > 100. For normalization, all probe sets were scaled
to a target intensity of 600 and scale mask files were not
selected.
Mapping Affymetrix probes to Agilent probes
Affymetrix probes were first mapped to UniGene Ids
using their publically available annotation table and then
subsequently mapped to Agilent probes using their
respective annotation table. Since many of the genes in
our panel are represented by multiple probes, the average
expression of each probe was measured across all samples
and the probe with the highest overall signal for each
gene in our panel was selected as the equivalent diagnos-
tic feature.
Description of the Genes@Work Software
We used a software package called Genes@Work [5] cre-
ated by IBM Research, to determine differentially
expressed genes in each tissue type. This software uses an
experimentally validated non-linear error model for gene
expression measurement error derived from replicate
measurements which underemphasizes the significance
of variations in genes that have lower expression and
overemphasizes the significance of variations in genes
that have high expression.
SVM Classifiers
All classifiers were built using SVM light http://svm-
light.joachims.org/ using a linear kernel option and com-
plete leave-one-out estimations were calculated for each
experiment. M-fold cross validation was also performed
at m = 5 and 300 samplings with replacement (Table 2).
Normalized data for each of the tissue types were sepa-
rated into normal and cancer classes and designated as
positive and negative classes respectively. Classifiers were
built for each tissue type separately as well as globally and
saved as SVM model files with support vector informa-
tion for future classification.
Results
Generating a common gene panel for cancer classification
I n  o r d e r  t o  e x p l o r e  t h e  p o s s i b i l i t y  o f  a  c o m m o n  g e n e
panel that can reliably detect cancer originated from mul-
tiple tissue types, we created a compendia of 5 microarray
datasets from prostate, lung, ovarian, colon, and breast,
respectively, each with cancer and normal samples from
multiple subjects (Table 1). Primary tumor samples and
normal samples were collected and processed on Affyme-
trix HG-U133A GeneChip and subsequently RMA nor-Irgon et al. BMC Cancer 2010, 10:319
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malized and uploaded to an internal database. The raw
intensity data was also log2 transformed, normalized and
then input to Genes@Work. This software uses an error
model based on replicate Affymetrix chip measurements
to determine the true error bounds and p-values and was
therefore was an ideal choice for this type of analysis. Fig-
ure 1 shows an example of the program output. Points
outside of the lines correspond to genes that are differen-
tially expressed with a p-value < 0.05. We generated one
set of significantly dysregulated genes for each tissue type
by comparing normal samples to tumor samples in that
tissue type. Table 1 shows the distribution of samples and
the corresponding differentially expressed genes.
Next, we identified the intersection of all genes differ-
entially expressed in all five tissue types, resulting in our
common cancer gene panel. Using leave-one-out (LOO)
cross validation as well as m-fold cross validation, we ver-
ified that our common "tumor discriminating" gene panel
was robust and could separate cancerous tissue from nor-
mal tissue with accuracies exceeding 90% when the tissue
of origin was known (see Table 2). Figure 2a shows the
relative expressions of each gene in our common feature
set in cancer and corresponding normal samples for each
tissue type. This figure also shows the expression trends
of each of the genes in our panel. A binary table repre-
senting this information including all probe ids used is
available in Table 3. Figure 2b depicts entire data set
grouped by phenotype (cancer versus normal) and dem-
onstrates the striking distinction in gene expression of the
panel genes between cancer and normal tissue. To vali-
date that our common caner signature can correctly and
robustly classify tumors, we applied our panel to data
from several published studies on tumors originating
from different tissue types. The results are summarized
in Table 4, and described in detail below.
Table 1: Sample distribution for each tissue, and number of differentially expressed genes as calculated by Genes@Work 
at p < 0.05 
Tissue type Sample distribution # of Differentially Expressed Gene probes
Prostate 7 Benign, 2 Normal, 10 Cancer 2035
Lung 37 Normal, 29 Cancer 1961
Ovarian 24 Normal, 22 Cancer 2717
Colon 4 Benign, 4 Normal, 33 Cancer 4159
Breast 6 Benign, 10 Normal, 31 Cancer 2704
Intersection 77 Normal, 125 Cancer 113
Table 2: Leave-one-out and m-fold CV accuracies for normal-tumor classification in our training data using our panel and 
a linear SVM classifier
Tissue Type Training LOO Accuracy M-fold CV Accuracy
Breast 94.73% 92.7%
Colon 96.41% 95.5%
Prostate 100.00% 99.9%
Lung 95.80% 97.3%
Ovary 96.20% 98.2%
Global 91.4% 90.9%Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
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Validation set #1: Lung Cancer
Spira et al identified an 80 gene panel which, together
with cytopathology, was able to distinguish smokers with
and without stage 1 lung cancer using bronchial epithelial
brushing samples [6]. Using a weighted voting algorithm,
they were able to achieve 80% accuracy which improved
to 95% when these predictions were combined with cyto-
pathology. In comparison, our gene panel applied to their
data and trained on an SVM classifier (without using
cytopathology) was able to achieve 94.75% leave-one-out
a c c u r a c y  u s i n g  t h e  m i c r o a r r a y  d a t a  a l o n e .  T o  m a k e  a
more direct comparison, we also built SVM classifiers
based on Spira's 80 gene probes, as well as the top 104
probes using the same feature extraction methodology
that they used. Figure 3 shows the distributions of accura-
cies for classifiers based on a random choice of genes
compared with our panel as well as Spira's original panel
described in the publication.
Although the data of Spira et al had samples from bron-
chial airway epithelial cells and our lung data was for pri-
mary lung cancer, the tumor samples in the datasets had
similar signatures with respect to the genes in our panel.
This was verified by checking that both SVM classifiers
using our gene panel, built on the Spira data and tested on
primary lung cancer data or vice versa, had classification
accuracy > 90%.
Validation set #2: Breast Cancer
Wang et al published a study with a 286 sample data set of
breast cancer samples, 180 from patients who eventually
developed distant metastasis within 5 years and 106 from
patients who did not [7]. Using both a breast specific and
the multi-tissue tissue SVM classifier, we classified all 286
of these samples as cancerous. Further, although we did
not expect a positive result, as an exploratory measure we
built a classifier that attempted to distinguish between
metastatic tumors and non-metastatic lesions. Our clas-
sifier achieved 88.8% LOO accuracy, suggesting that
although it was developed to distinguish tumors from
normal, some of these genes seem to also carry informa-
tion about the metastatic properties of these tumors.
Validation set #3: Ovarian Cancer
Data from the Dana Farber Cancer Institute GCOD data-
set repository[8] was selected for high-throughput valida-
t i o n  o f  o u r  c a n c e r  s i g n a t u r e s .  W e  s e l e c t e d  d a t a  f r o m
ovarian and colon tissue which had data points for all 113
of our probes. The array normalized data was then tested
using SVM classifiers trained on our data set. Summaries
of the results of this analysis are included in Table 4 and
show that our panel is highly accurate.
Study 1: [9]: 103 samples ranging from mucinous, clear
cell, serious and endometrioid ovarian carcinomas.
Figure 1 Example of Genes@Work feature selection. Genes@ Work [5] output for cancer and matched normal sample from the Lung Cancer data-
set. Normalized gene expression values for each gene from the cancer and normal sample are plotted on the X and Y axes respectively. The solid blue 
lines defines statistical significance boundaries at p = 0.05 from the experimental error model. Red points lying outside above and below the solid 
lines are gene expression values which are significantly different at p < 0.05 between cancer and normal samples.Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
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Study 2: [10] 27 samples, 23 cancer, 4 normals.
Using both an ovarian specific classifier & a multi-tis-
sue classifier, we obtained 100% accuracy.
Validation set #4 Colon cancer
Study 1: Groene et al [11] 36 samples ranging conven-
tional mucinous, serated mucinous, serated non-muci-
nous.
Study 2: Laiho et al [12]: 37 samples which were all col-
orectal adenocarcinomas.
Using a colon specific classifier & a multi-tissue classi-
fier we were able to correctly label all cancer samples.
T o further test the significance of our gene panel, we
used an internal data warehouse called tranSMART (pri-
vate communication, J. Smart, Centocor R&D, Inc) that
takes a gene signature as input and searches all deposited
internal and public clinical and non-clinical microarray
analyses for similar signatures. When inputting our
multi-tissue average signature, the top significant results
all refer to normal vs cancer comparisons. Our global sig-
nature hit 47% of the cancer vs. normal comparisons
which was significant relative to the total distribution
that only comprises 5% of the database. We then tested
the top publicly available hits to see how accurately we
could predict the two classes. Specifically, we tested two
datasets containing tissue types outside the scope of our
training set.
Validation set #5: Bladder cancer and Melanoma
The first dataset analysed was a bladder cancer dataset
from Dyrskjot et al [13] containing 60 samples, 9 of which
were normal and the rest were superficial transitional cell
carcinoma with and without surrounding carcinoma in
situ. The second [14] had 7 normal skin samples and 45
Figure 2 Expression and signature trends of the training data. 2a - Signature trends of each tissue type. Red designates genes that are on average 
over-expressed when compared to their tissue's average normal expression. Black designates under expression versus normal. 2b - Combined training 
data for Lung, Breast, Ovarian, Prostate and Colon tissue samples grouped by phenotype and ranked by the ratio of differential gene expression. Tu-
mors are on the left and normals are on the right.Irgon et al. BMC Cancer 2010, 10:319
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Table 3: Gene Names, Affymetrix Probe Ids and their corresponding signatures in each tissue type
Genes Affy ID Global Lung Colon Breast Prostate Ovary
ABAT 209459_s_at -1 -1 -1 11 -1
ACTA2 200974_at -1 -1 -1 -1 -1 -1
AMIGO2 222108_at -1 -1 1 -1 -1 -1
ANK2 202920_at -1 -1 -1 -1 -1 -1
BHLHB3 221530_s_at -1 -1 1 -1 -1 1
C17orf91 214696_at -1 -1 -1 -1 -1 -1
C1orf115 218546_at -1 -1 -1 -1 1 -1
CAV1 203065_s_at -1 -1 1 -1 -1 -1
CAV1 203065_s_at -1 -1 1 -1 -1 -1
CUGBP2 202158_s_at -1 -1 1 -1 -1 -1
CXCL2 209774_x_at -1 -1 1 -1 -1 -1
CYLD 39582_at -1 -1 -1 -1 -1 -1
DCN 201893_x_at -1 -1 1 -1 -1 -1
DKK3 214247_s_at -1 -1 1 -1 -1 -1
DMN 212730_at -1 -1 -1 -1 -1 -1
DPYSL2 200762_at -1 -1 1 -1 -1 -1
DST 212254_s_at -1 -1 -1 -1 -1 -1
DST 212254_s_at -1 -1 -1 -1 -1 -1
EDNRB 204273_at -1 -1 -1 -1 -1 -1
EFEMP1 201842_s_at -1 -1 1 -1 -1 -1
EGR1 201694_s_at -1 -1 -1 -1 1 -1
EPB41L2 201719_s_at -1 -1 1 -1 -1 -1
FBLN1 202995_s_at -1 -1 11 -1 -1
FERMT2 209210_s_at -1 -1 1 -1 -1 -1
FHL1 201540_at -1 -1 -1 -1 -1 -1
GSN 200696_s_at -1 -1 -1 -1 -1 -1
GSTM5 205752_s_at -1 -1 -1 -1 -1 -1
H3F3A///H3F3B 211998_at -1 -1 1 -1 -1 -1
HBA1///HBA2 209458_x_at -1 -1 -1 -1 1 -1
HBA1///HBA2 209458_x_at -1 -1 -1 -1 1 -1
HBA1///HBA2 209458_x_at -1 -1 -1 -1 1 -1
HBB 209116_x_at -1 -1 -1 -1 1 -1
HBB 209116_x_at -1 -1 -1 -1 1 -1
HBB 209116_x_at -1 -1 -1 -1 1 -1
JAM3///LOC100133502 212813_at -1 -1 -1 -1 -1 -1
JUN 201466_s_at -1 -1 1 -1 1 -1
LAMA4 202202_s_at -1 -1 1 -1 -1 -1
MAOA 212741_at -1 -1 -1 -1 1 -1
MBNL1 201153_s_at -1 -1 -1 -1 -1 -1
ME1 204059_s_at -1 1 -1 -1 -1 -1
MEIS1 204069_at -1 -1 1 -1 -1 1
METTL7A 207761_s_at -1 -1 -1 -1 -1 -1
MT1P2 211456_x_at -1 -1 -1 -1 11
MYLK 202555_s_at -1 -1 -1 -1 -1 -1Irgon et al. BMC Cancer 2010, 10:319
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NR3C1 211671_s_at -1 -1 -1 -1 -1 -1
OPTN 202073_at -1 -1 -1 -1 -1 -1
PAM 202336_s_at -1 -1 1 -1 -1 -1
PDGFRA 203131_at -1 -1 -1 -1 -1 -1
PDLIM3 209621_s_at -1 -1 1 -1 -1 -1
PLSCR4 218901_at -1 -1 -1 -1 -1 -1
PPAP2A 210946_at -1 -1 -1 -1 1 -1
PPAP2B 212230_at -1 -1 -1 -1 -1 -1
RAB31 217762_s_at -1 -1 11 -1 -1
RBPMS 209487_at -1 -1 1 -1 -1 -1
RCAN2 203498_at -1 -1 -1 -1 -1 -1
RNASE4 205158_at -1 -1 -1 1 -1 -1
SEPP1 201427_s_at -1 -1 -1 -1 1 -1
SERPINA1 211429_s_at -1 -1 -1 1 -1 1
SORBS1 218087_s_at -1 -1 -1 -1 -1 -1
SPARCL1 200795_at -1 -1 1 -1 -1 -1
SRPX 204955_at -1 -1 1 -1 -1 -1
STOM 201060_x_at -1 -1 -1 1 -1 -1
SYNPO 202796_at -1 -1 -1 -1 -1 -1
TMEM140 218999_at -1 -1 -1 -1 -1 -1
TMEM47 209656_s_at -1 -1 1 -1 -1 -1
TNS1 221748_s_at -1 -1 -1 -1 -1 -1
TSC22D3 208763_s_at -1 -1 -1 11 -1
TUBA1A 209118_s_at -1 -1 1 -1 -1 -1
WWTR1 202133_at -1 -1 1 -1 -1 -1
ZFP36L2 201368_at -1 -1 -1 -1 -1 -1
ACTR3 200996_at 11-1 1 -1 1
C7orf24 215380_s_at 1 1 1111
CALR 214315_x_at 1 1 1111
CKS2 204170_s_at 1 1 1111
COL6A2 209156_s_at 11 1 1 -1 -1
CXCL1 204470_at 11 1 -1 -1 1
DHCR24 200862_at 1 -1 -1 111
FABP5///FABP5L2///FABP5L7 202345_s_at 1 -1 1 -1 11
GALNT7 218313_s_at 11-1 111
GAPDH M33197_5_at 11 1 1 -1 1
GAPDH M33197_5_at 11 1 1 -1 1
HDGF 200896_x_at 1 1 1111
HIST1H2AC 215071_s_at 11-1 111
HIST1H2BD 209911_x_at 11-1 111
HIST1H2BK 209806_at 1 1 1111
HIST2H2AA3///HIST2H2AA4 214290_s_at 1 1 1111
HN1L 212115_at 1 1 1111
KIAA0101 202503_s_at 1 1 1111
KRT19 201650_at 11-1 1 -1 1
KRT8 209008_x_at 11-1 111
LAPTM4B 214039_s_at 11 1 -1 -1 1
Table 3: Gene Names, Affymetrix Probe Ids and their corresponding signatures in each tissue type (Continued)Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
Page 8 of 11
melanoma samples. An interesting visualization of this
dataset is available in Additional File 1. Note that our
gene panel demonstrates an incomplete transformation
signature of the benign nevi in this data set. An analysis
combining these two data sets using our SVM classifier
yielded 95.2% LOO accuracy for distinguishing tumor
from normal (Table 4).
Validation set #6: Clear Cell Renal Cell Carcinoma (ccRCC)
To establish how well our panel performed for ccRCC/
normal-kidney discrimination we used a previously pub-
lished dataset which was also used by two other groups
[2,3] in testing their gene lists to distinguish ccRCC from
normal kidney. We downloaded the data the GSE781
dataset from GEO http://www.ncbi.nlm.nih.gov/gds/
?term=GSE781 and applied our SVM classifier on this
data to distinguish ccRCC from normal kidney. The
results are shown in Table 5. At first pass, we noticed that
our gene panel performed poorly on this dataset. TMEV
[15] visualization of this dataset using our gene panel
revealed that several of the samples with sample headings
listed as cancerous very closely resembled normal sam-
LOC100130414///SPINT2 210715_s_at 11-1 111
LRRFIP1 201861_s_at 1 -1 -1 111
LSR 208190_s_at 11-1 111
MCM2 202107_s_at 1 1 1111
MIF 217871_s_at 1 1 1111
MLF1IP 218883_s_at 1 1 1111
MLPH 218211_s_at 1 -1 -1 111
NME1///NME2 201577_at 1 1 1111
NOLA2 209104_s_at 1 1 1111
NPM1 221923_s_at 11 1 -1 11
NUSAP1 218039_at 1 1 1111
P4HB 200654_at 1 1 1111
PABPC3 208113_x_at 11 1 -1 11
PDIA4 211048_s_at 1 1 1111
PMM2 203201_at 11-1 111
RNASE2 215193_x_at 1 -1 11 -1 1
RRBP1 201204_s_at 11-1 111
SORD 201563_at 1 1 1111
TACSTD1 201839_s_at 11-1 111
TMED3 208837_at 1 1 1111
YWHAZ 200641_s_at 11-1 1 -1 1
ZWINT 204026_s_at 1 1 1111
1 (Blue) represents upregulated with respect to normal and -1 (Red) downregulated.
Table 3: Gene Names, Affymetrix Probe Ids and their corresponding signatures in each tissue type (Continued)
Table 4: Leave-one-out and validation accuracies for normal-tumor classification in various tissue types using our panel 
and a linear SVM classifier
Data Set Accuracy
Multi-tissue SVM on Wang Data[5] 100%
Breast Cancer Metastasis Training [5] 88.80%
Multi-tissue SVM on Ovarian Cancer GCOD (2 studies) [7,8] 100%
Multi-tissue SVM on Colon Cancer GCOD (2 studies) [9,10] 100%
Other tissue validation sets (Bladder, Melanoma, ccRCC) [11,12] 95.4%Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
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ples (Additional File 2). Furthermore, a careful analysis of
the tumor and normal labels in the original data showed
that these three samples were indeed normal. Apparently,
these three samples were misinterpreted as tumors in the
analysis of Rhodes et al [2] and Xu et al [3](we describe
this issue further in the discussion section). After prop-
erly labelling these samples as normal, our SVM had
100% testing accuracy in distinguishing ccRCC from nor-
mal kidney.
To further test our accuracy on ccRCC we also analyzed
a microarray dataset from an on-going collaboration at
the University of North Carolina Medical School consist-
ing of 52 ccRCC samples and 18 patient matched normal
kidney samples from two studies [16-18]. The data was
collected on Agilent G4112F whole genome arrays and is
posted on GEO (GSE16449). After mapping our Affyme-
trix probe features to genes, we created a dataset where
the level of each gene was represented as the expression
level of the probe (for that gene) with the highest average
expression across samples (see methods). This reduced
the dataset to 100 genes, on which we applied our SVM
analysis methodology to distinguish ccRCC from normal
kidney. The SVM also had 100% leave-one-out cross vali-
dation accuracy on these samples, which suggests that
our panel is not only robust across tissue types but also
appears to be platform independent. TMEV [15] visual-
izations of this dataset is also available in Additional File
3.
Discussion
For the public datasets we used, the pathological stage is
given in the papers cited above. For the proprietary data-
sets, Additional File 4 details all the staging information
we have on the tumor samples. We have identified a
robust panel of commonly differentially expressed genes
from 77 normal tissues and 125 cancer samples and dem-
onstrated that these features capture the neoplastic ele-
ments of the cancer samples in sufficient detail across
many tumor types to provide an accurate diagnostic for
cancer detection. Some of the genes in our panel have
been previously indicated in cancer association studies.
For example, KIAA0101 (p15PAF) is a PCNA associated
factor which has been shown to be upregulated in tumor
samples [19]. This gene as well as two others, NME1 and
CKS2, is also present in both the Rhodes and Xu signa-
tures [2,3]. However, there are some unexpected discov-
eries. For example, we found GAPDH, generally believed
to be a housekeeping gene, upregulated in tumors vs.
normal in all tissue with the exception of prostate tissue
where it had the opposite signature. Our results are in
agreement with a recent observation [20] that several
housekeeping genes, including GAPDH, have a differen-
tial signature in tumors versus normal tissue.
When the gene signature is analysed for its functional
classifications, it becomes clear that it is enriched in cate-
gories important for cell growth. Among the highly
enriched categories include actin cytoskeleton organiza-
tion, DNA packaging, nucleosome and chromatin assem-
bly, and regulation of blood vessel size.
While the Rhodes and Xu gene panels have demon-
strated similar success in diagnostic capabilities our gene
panel is more robust both in design and performance
(Table 5). Our panel outperformed the panels by Rhodes
et al [2] and Xu et al [3] in 4 out of 6 tumor types while
Figure 3 Distribution of LOO accuracies. Distribution of LOO accuracies using randomly selected gene lists to classify Lung cancer from the dataset 
of Spira et al. [6], overlayed with accuracies using the dataset from [6] compared to our gene panel.Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
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performed equally well for the remaining two. Taken as a
whole, our panel achieved 96% accuracy. It should be
noted, however, that three samples interpreted as ccRCC
in the Rhodes et al [2] and Xu et al [3] studies were actu-
ally normal samples in the original dataset and thus the
sample headings were misleading. For instance, one of
the samples interpreted as "tumor" in the Rhodes et al [2]
and Xu et al [3] studies had the description: "N4 Renal
Cell Carcinoma" in GEO. However, the detailed descrip-
tion in the original data read: "Trizol isolation of total
RNA from normal tissue adjacent to Renal Cell Carci-
noma", which meant that this sample should have been
classified as Normal Kidney. In the analysis done by Rho-
des et al [3] and Xu et al [4], these errors were not cor-
rected, which may partly explain their poor results on this
dataset. The three samples which are misinterpreted in
the GEO database as tumor are sample IDs: GSM12283,
GSM12300, GSM12444. After properly labelling these
samples as normal, our SVM had 100% testing accuracy
in distinguishing ccRCC from normal kidney.
The reason for the robustness of the panel is that we
use a methodology (Genes@Work) where the error
model for expression levels (noise) is derived from actual
replicate measurements [5] rather than from assuming
that the underlying error is Gaussian, which is implicit in
the error models used in other panels. On a practical
level, our panel performs remarkably well in unseen test-
ing datasets, many of which were on tissue types which
were outside the tissue sets in the training data. Due to
the robustness of our gene panel, it should be particularly
useful in accurate identification of mislabelled or misin-
terpreted samples.
Conclusions
Our feature set has several potential uses. A common
problem of cancer sample collection is that surrounding
normal tissue can severely contaminate the sample. Since
the tissue of origin is usually known in biopsies, our panel
can be used as a tool for rapid determination of the pres-
ence or absence of cancer cells as an aid to pathologists. It
can also be used to determine contamination in in-vitro
experiments.
Expression-based diagnosis and risk assessment is rap-
idly gaining popularity in the clinic [21] with diagnostic
panels using measurements of 10 to 35 genes via qRT-
PCR experiments. A possible follow up to our study
would be to identify and validate a minimal subset of
probes which retain sufficient predictive power and
which can be measured using RT-PCR from FFPE sec-
tions.
Additional material
Additional File 1 Melanoma data set (GSE 3189) visualization. Mela-
noma data set (GSE 3189) gene expression sorted by ratio of gene expres-
sion ratio of cancer vs. normal. The middle portion contains nevus samples 
which are considered benign. Interestingly, they appear to have a mixed 
signature that is an incomplete transformation from normal to cancer.
Additional File 2 The kidney cancer validation sets. Samples on the left 
are normal, right are cancer. The first image represents the Lenburg et al. 
[19] data set. The mislabelled samples in question are the rightmost 3 sam-
ples in the normal subgroup.
Table 5: Comparison with the Rhodes and Xu signatures on the same independent data
Rhodes 
Signature
Xu 
Signature
Our 
Signature
GSE# Accuracy(%) P-value Accuracy(%) P-value Accuracy(%) P-value
Gordon_Lung GSE2549 91.8 3.48E-07 95.9 1.75E-07 97.8 3.50E-09
Hoffman_Myometrium GSE593 80 2.06E-01 80 8.33E-02 90 8.00E-04
Lenburg_Kidney GSE781 76.5 1.01E-01 76.5 1.07E-01 76.5|100* 1.00E-10
Talantov_Skin GSE3189 94.2 8.97E-07 98.1 3.44E-07 94.2 5.11E-04
Wachi_Lung GSE3268 100 3.97E-03 100 3.97E-03 100 3.97E-03
Yoon_Soft_Tissue GSE2719 85.2 5.67E-08 96.3 6.76E-11 94.3 9.50E-07
Overall 89.1 9.28E-26 94.3 9.74E-30 96 1.04E-30
*100% Accuracy achieved after labelling is corrected.Irgon et al. BMC Cancer 2010, 10:319
http://www.biomedcentral.com/1471-2407/10/319
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